Orforglipron tablets are primarily indicated for glycemic control in type 2 diabetes mellitus and weight management in obesity/overweight. They break through the limitations of traditional injectable GLP‑1 agents and highlight the convenience of oral administration. Compared with other oral peptide formulations, these tablets feature higher bioavailability, more mature small‑molecule synthetic processes, and lower costs.
Our Products Form
Orforglipron COA
Clinical Research Progress in the Treatment of Peripheral Vascular Diseases
At present, orforglipron tablets have entered Phase III clinical trials for the treatment of peripheral vascular diseases (PVD). Multiple early studies and trial designs have preliminarily validated their application potential in this field, with the most concentrated research focused on Fontaine Stage II peripheral artery disease (PAD), mainly presenting as intermittent claudication. This is the most common clinical stage of PVD, in which patients experience severely impaired quality of life yet lack effective metabolic interventions.
The ongoing Phase III trial is designed as a randomized, double‑blind, placebo‑controlled study. It plans to enroll 1,205 patients globally, including 120 at Chinese sites, with an approximate duration of 58 weeks. The trial primarily evaluates the efficacy and safety of once‑daily oral tab in patients with PAD.The primary endpoint is the percentage change in maximum walking distance. Secondary endpoints include changes in pain‑free walking distance, VascuQoL‑6 score (vascular disease quality of life), 6‑minute walking distance, high‑sensitivity C‑reactive protein, and systolic blood pressure, comprehensively covering core therapeutic goals: symptom improvement, vascular function recovery, and inflammation control.During the trial, patients receive oral this med with titration up to a maximum dose of 36 mg, compared with placebo or standard care. Efficacy is further assessed using imaging examinations such as the ankle‑brachial index (ABI) and patient‑reported outcomes (PRO).
Early clinical studies and relevant meta‑analyses have provided strong support for the Phase III trial. Research shows that it exerts significant weight reduction, glycemic control, and lipid‑modulating effects. At the highest dose, patients achieved an average weight reduction of 12.4% over 72 weeks, and a maximal HbA1c reduction of 2.2%, superior to oral semaglutide. It also significantly improves the lipid profile and reduces the accumulation of atherosclerotic risk factors.Furthermore, preclinical studies indicate that this can improve vascular endothelial function, reduce vascular inflammation, effectively delay the formation and progression of atherosclerotic plaques, and lower the risk of peripheral vascular occlusion. It is particularly suitable for PVD patients with comorbid diabetes and obesity-high‑risk populations often poorly responsive to conventional therapies. The multi‑metabolic regulatory effects of it achieve a "one‑drug, multiple‑benefits" strategy, simultaneously managing underlying metabolic diseases and vascular lesions.
Notably, the clinical trial defines strict inclusion and exclusion criteria to ensure the specificity and reliability of results.
Inclusion criteria: Fontaine Stage II PAD with intermittent claudication, ABI ≤ 0.9, BMI ≥ 23 kg/m².
Exclusion criteria: HbA1c >10%, walking impairment due to non‑PAD conditions, planned lower‑extremity surgery or recent peripheral arterial revascularization, recent stroke or myocardial infarction, New York Heart Association Class III–IV heart failure, etc., to avoid confounding from other diseases.
The data and information in this section are sourced from:
Li Juan, Wang Hao, Zhang Ying. Research progress on oral GLP-1 receptor agonist orferglipron. Chinese Journal of New Drugs, 2024, 33 (12): 1389-1396
Chen Xi, Liu Min. The application prospect of orferglipron, a non peptide GLP-1 agonist, in obesity and type 2 diabetes. Chinese Journal of Endocrinology and Metabolism, 2025, 41 (2): 156-160
Zhao Yang, Sun Yue The mechanism of action and clinical research progress of Orferglipron. Journal of Clinical Drug Therapy, 2025, 23 (5): 45-50
Application Scenarios and Advantages in Peripheral Vascular Diseases
Based on its mechanism of action and clinical development, it have well‑defined application scenarios in PVD, especially in patients with metabolic disorders, providing complementary benefits to existing treatments and optimizing therapeutic regimens.
First‑line adjuvant therapy for PVD patients with comorbid diabetes/obesityApproximately 60% of PVD patients have diabetes or obesity. In these patients, atherosclerosis progresses faster, limb ischemia is more severe, and conventional therapies rarely control both metabolic disorders and vascular disease simultaneously.
As an oral formulation, orforglipron tablets improve glycemic control and reduce weight while exerting vascular protective effects, delaying disease progression and lowering the risk of limb ulcers, gangrene, and cardiovascular adverse events. Compared with injectable GLP‑1 drugs, its convenience greatly improves long‑term adherence, making it a suitable long‑term adjuvant option. Clinical data confirm superior glycemic and weight control versus oral semaglutide, along with improved lipid metabolism and further reduction of atherosclerotic risk, offering comprehensive protection for high‑risk patients.
Postoperative adjuvant rehabilitation therapy for PVDSevere PVD often requires interventional therapy (e.g., balloon angioplasty, stenting) or surgical bypass grafting. However, postoperative issues such as restenosis and exacerbated inflammation remain major challenges.It can reduce the risk of postoperative restenosis, promote vascular function recovery, control metabolic risk factors including blood glucose and body weight, improve rehabilitation quality, and lower recurrence rates by suppressing inflammation, improving endothelial function, and regulating metabolic disorders. Its oral formulation avoids injection difficulties in patients with limited limb mobility, further enhancing convenience and adherence.
Alternative therapy for patients intolerant to injectable agentsTraditional GLP‑1 therapies are mostly injectable. Some PVD patients struggle with long‑term injection due to limb ischemia, limited mobility, or injection aversion, leading to treatment interruptions and disease recurrence.As the world's first oral small‑molecule non‑peptide GLP‑1 receptor agonist in late‑stage clinical development, it completely overcome the limitations of injection. Once‑daily oral administration requires no professional procedure and allows self‑medication, effectively solving the pain points of injectable therapy. It provides a viable option for patients intolerant to injections, improving adherence and ensuring treatment continuity.
Compared with current PVD medications, the core advantages of it lie in the combination of pleiotropism and convenience. Existing drugs mostly have single actions: antiplatelets prevent thrombosis, lipid‑lowering agents control lipids, and few achieve coordinated metabolic regulation and vascular protection. Orforglipron simultaneously delivers glycemic control, weight reduction, lipid modulation, anti‑inflammation, and endothelial protection, intervening in PVD pathogenesis across multiple dimensions.
Meanwhile, the oral dosage form requires no refrigeration, is portable, and easy to administer, greatly reducing patient burden-ideal for chronic conditions requiring long‑term management. It effectively improves medication adherence and clinical outcomes.
The data and information in this section are sourced from:
Frias J, Blevins T, et al. Efficacy and safety of oral orferglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet, 2023, 402(10400): 472-483.
Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by orferglipron (LY3502970), an orally active nonpeptide agonist. Proc Natl Acad Sci U S A, 2020, 117(47): 29959-29967.
Ma X, Liu R, Pratt EJ, et al. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orferglipron (LY3502970). Diabetes Ther, 2024, 15(4): 819-832.
Application Prospects and Outlook
Peripheral vascular disease is a highly prevalent chronic condition with unmet needs: limited pharmacologic options, poor patient adherence, and difficulty managing multiple risk factors simultaneously. The global market is projected to exceed $30 billion by 2030.As a novel oral GLP‑1 receptor agonist, the product, with their pleiotropism, convenience, and favorable safety profile, are expected to fill the gap in metabolic‑targeted therapy for PVD and reshape the treatment landscape, especially for patients with comorbid diabetes and obesity, supporting broad clinical prospects.
The global Phase III trial for PVD, including Chinese sites, is ongoing and expected to complete and release results in 2028. If successful, this may obtain PAD approval in 2027–2028, becoming the first GLP‑1 agent approved primarily for PAD and expanding its clinical utility to benefit more patients.With further clinical development, its patient population will be better defined, and regimens optimized. Orforglipron may benefit broader PVD subtypes (e.g., renal and mesenteric artery disease) and integrate with interventional and surgical therapies to form a comprehensive system, improving outcomes, reducing disability and mortality, and enhancing quality of life.
Additionally, the successful development of oral small‑molecule it provides a new paradigm for PVD treatment, driving the evolution of GLP‑1 agents from "weight‑loss drugs" to "cardiovascular protectors." It is expected to encourage more oral GLP‑1 therapies for PVD, fostering competition and optimizing care.Its mature small‑molecule synthesis and lower cost versus peptide drugs may improve accessibility to innovative PVD therapies, allowing more patients to benefit from medical advances.
The data and information in this section are sourced from:
Pratt E, Ma X, Liu R, et al. Orferglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab, 2023, 25(9): 2634-2641.
Wharton S, Blevins T, Connery L, et al. Daily oral orferglipron for adults with obesity. N Engl J Med, 2023, 389(10): 877-888.
Dutta D, Nagendra L, Anne B, et al. Orferglipron, a novel non-peptide oral daily GLP-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obes Sci Pract, 2024, e743.
I. API Synthetic Process
The active pharmaceutical ingredient (API) of orforglipron tablets is orforglipron, manufactured via a multi‑step chemical synthesis. The key challenges are chiral purity control and impurity management.The synthesis uses indole‑2‑carboxylic acid and imidazol‑2‑one intermediates as critical building blocks. The traditional route required 28 steps; it has now been optimized to an efficient 16‑step process, greatly improving scalability.A copper‑catalyzed Ullmann reaction replaces the conventional palladium‑catalyzed route, reducing production costs while increasing the overall yield of the key intermediate to 80%. Diastereomeric impurities are controlled below 1.5%, ensuring chiral purity above 99.9% and minimizing adverse effects from inactive isomers.
II. Tablet Manufacturing Process
The tablets employ standard oral solid‑dosage manufacturing, without complex sterile filling, enabling large‑scale assembly‑line production.The process consists of four main stages:
Formulation & blending: API is uniformly mixed with excipients (fillers, disintegrants, etc.) in precise ratios to ensure content uniformity.
Compression: Blended powder is compressed into uncoated tablets under controlled pressure, with hardness optimized for integrity and disintegration rate.
Film coating: Coating improves stability, masks bitterness, and does not impair dissolution or absorption, ensuring rapid onset after oral administration.
III. Quality Control Standards
The entire manufacturing process complies with GMP standards, supported by a multi‑stage quality control system.
API control: HPLC combined with mass spectrometry is used to strictly control genotoxic impurities below safety thresholds and ensure API purity.
Formulation control: Key parameters include content uniformity, disintegration time, and dissolution rate, with dissolution meeting USP <621> requirements and peak resolution ≥ 2.0.
Environmental & release control: Real‑time monitoring of temperature, humidity, and cleanliness. Every batch undergoes rigorous testing and is released only with a Certificate of Analysis (COA).
FAQ
This is not currently available for purchase for human consumption as it is still in late-stage (Phase 3) clinical trials, with potential FDA approval and market availability expected around mid-to-late 2026. It is a new, investigational daily oral GLP-1 receptor agonist for obesity and type 2 diabetes.
As a once-daily oral agent, orferglipron has no strict restrictions on meal time. It shows steady weight-losing efficacy in clinical trials with mild and tolerable gastrointestinal side effects, suitable for long-term weight maintenance and auxiliary glycemic regulation.
Orferglipron works by suppressing appetite, enhancing satiety and delaying gastric emptying. It also promotes glucose-dependent insulin secretion and optimizes energy metabolism, delivering dual benefits of weight management and blood sugar control for overweight and diabetic populations.
Orferglipron is an oral small-molecule GLP-1 receptor agonist with non-peptide structure. It simulates the physiological function of endogenous GLP-1 in the human body and features high oral bioavailability, making it a convenient alternative to injectable GLP-1 preparations for metabolic regulation.
It is an experimental daily oral GLP-1 receptor agonist for weight loss that causes primarily mild-to-moderate gastrointestinal side effects, including nausea, diarrhea, constipation, vomiting, and abdominal pain. These effects are most common during initial dose escalation and typically subside over time.
Hot Tags: orforglipron tablets, China orforglipron tablets manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, unicalcin 100, glp1 shot, etelcalcetide structure
